β-galactosidase (β-gal), a protein product of the bacterial LacZ gene, catalyzes the conversion of β-galactosides into monosaccharides. β-gal is a common marker gene used to assess transfection efficiency.

• Capped with CleanCap® AG cap analog, no base modifications in the sequence

  Cap 1 structure with >95% capping efficiency for superior in vivo activity compared to Cap-0 mRNAs

  Manufactured with TriLink’s proprietary CleanScript® method to lower dsRNA for improved performance

  Ready to use in downstream mRNA applications and formulations

  Grade: RUO

This mRNA is capped using CleanCap® Reagent AG, TriLink's co-transcriptional capping technology, which results in the naturally occurring Cap-1 structure with >95% capping efficiency. It is manufactured using TriLink’s CleanScript® method, polyadenylated, and optimised for mammalian systems. It mimics a fully processed mature mRNA.

CleanCap Reagent AG produces a base-modified Cap-1 mRNA, which shows superior in vivo activity compared to Cap-0 mRNA produced by legacy capping methods such as mCap or anti-reverse cap analog (ARCA).

CleanScript method is TriLink’s proprietary in vitro transcription process that is optimised to minimise dsRNA formation and increase mRNA activity in vivo.